Publications by authors named "Doris Zane"

Claim this Profile
C
Contemporary perspective and practical application of glutamate dehydrogenase in nonclinical studies.
Ravindra C Kodihalli, Mehrdad Ameri, Kevin S Baker, Samantha C Faber, Armando R Irizarry Rovira, Doris Zane

Biomark Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Bis-Acyl Hydrazides as Potent and Bioavailable MTA-Cooperative PRMT5 Inhibitors: A Case Study of Leveraging the Deuterium Kinetic Isotope Effect.
Laurent Debien, Megan K Armstrong, Joshua D Farr, Ryan D Ferrao, Pancham Lal Gupta, Doris Zane

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Industry Perspective on Nonclinical Approaches for Hepatotoxicity Risk Assessment: Insights from Two Longitudinal Surveys Conducted in 2023 and 2017.
Melanie Z Sakatis, Leah M Norona, Jamie E Karmel, William R Proctor, Fatou H Sarr, Doris Zane

Chem Res Toxicol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider.
Lise I Loberg, William R Proctor, Andrew D Burdick, Annick Cauvin, Anthony M DeLise, Doris T Zane

Regul Toxicol Pharmacol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessment.
Arianna Bassan, Ronald Steigerwalt, Douglas Keller, Lisa Beilke, Paul M Bradley, Doris Zane

Front Toxicol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges Associated with Biological Safety Assessments for Drug-Device Combination Products.
Cheryl L M Stults, Diane Harper, Doris Zane

PDA J Pharm Sci Technol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toxicologic Pathology Forum: Opinion on Not Euthanizing Control Animals in the Recovery Phase of Non-Rodent Toxicology Studies.
Kyathanahalli S Janardhan, Radhakrishna Sura, Smita Salian-Mehta, Thierry Flandre, Xavier Palazzi, Doris Zane

Toxicol Pathol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Regulatory Challenges for Peptide Therapeutics.
Doris Zane, Paul L Feldman, Tomi Sawyer, Zhanna Sobol, Jessica Hawes

Int J Toxicol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Doris Zane, Shane Roller, Josephine Shelton, Roshni Singh, Rachna Jain

Microbiol Spectr· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
Joseph W Romano, Marc M Baum, Zach R Demkovich, Frank Diana, Charles Dobard, Doris Zane

AIDS Res Hum Retroviruses· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resolution of unexpected pregnancy-related findings in a rat embryofetal development and toxicokinetic study of monoclonal antibodies specific for hCMV.
Paula Katavolos, Rodney Prell, Doris Zane, Rong Deng, Wendy Halpern

Birth Defects Res· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis